Cochrane · systematic review · CD008146
Interventions for fatigue in peripheral neuropathy
White, CM, van Doorn, PA, Garssen, MPJ, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
8
No studies
5
Included studies
NR
No studies 5 · 33.3%Ungraded 2 · 13.3%Very low 0 · 0%Low 2 · 13.3%Moderate 6 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Amantadine versus placebo for fatigue in Guillain‐Barré syndrome
Population: people with fatigue in Guillain‐Barré syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in fatigue of at least 1‐point on the Fatigue Severity Scale between 4 to 12 weeks after commencement of intervention Fatigue Severity Scale (FSS) from 1 to 7 (higher score is worse) Amantadine vs placebo | OR 0.56 [0.22, 1.35] | 74 participants | Low Downgraded: imprecision |
Change in fatigue 12 or more weeks after commencement of intervention (not measured) Amantadine vs placebo | no estimate extracted | NR | No studies |
Change in activity limitation 12 or more weeks after commencement of intervention (not measured) Amantadine vs placebo | no estimate extracted | NR | No studies |
Change in participation 12 or more weeks after commencement of intervention using the Rotterdam Handicap Scale. Scale from: 0 to 36. Amantadine vs placebo | no estimate extracted | 74 participants | Low Downgraded: imprecision |
Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) Amantadine vs placebo | no estimate extracted | NR | No studies |
Serious adverse events Amantadine vs placebo | no estimate extracted | 80 participants | Ungraded |
Ascorbic acid versus placebo for fatigue in peripheral neuropathy
Population: people with fatigue in peripheral neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in fatigue of at least 1 point on the Fatigue Severity Scale (FSS) between 4 to 12 weeks after commencement of intervention (not measured) Ascorbic acid vs placebo | no estimate extracted | NR | No studies |
Change in fatigue 12 or more weeks after commencement of intervention Visual Analogue Scale (VAS) of fatigue Ascorbic acid vs placebo | no estimate extracted | 2 studies · 404 participants | Moderate |
Change in activity limitation (ODSS/ONLS) Ascorbic acid vs placebo | no estimate extracted | 2 studies · 406 participants | Ungraded |
Change in 10 metre timed walk 12 or more weeks after commencement of intervention Time taken to walk 10 metres in seconds Ascorbic acid vs placebo | no estimate extracted | 2 studies · 406 participants | Moderate |
Change in speed of completion of 9‐hole peg test (in seconds) Ascorbic acid vs placebo | no estimate extracted | 1 study · 224 participants | Moderate |
Health‐related quality of life 12 or more weeks after commencement of the intervention Change in SF‐36 physical function score SF‐36 Physical Functioning Scale and Physical Component Score Ascorbic acid vs placebo | no estimate extracted | 2 studies · 400 participants | Moderate |
Change in participation 12 or more weeks after commencement of intervention (not measured) Ascorbic acid vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life 12 or more weeks after commencement of the intervention Change in mental function score of SF‐36 SF‐36 Mental Component Score Ascorbic acid vs placebo | no estimate extracted | 1 study · 123 participants | Moderate |
Serious adverse events Ascorbic acid vs placebo | RR 0.7 [0.39, 1.27] | 2 studies · 450 participants | Moderate |